CMN Weekly (17 January 2025) - Your Weekly CRISPR...
CMN Weekly
Jan. 17, 2025
Relevant Interviews, Webinar and Trial Updates posted by CRISPR Medicine News.
Always stay updated with the free CMN Newsletter.
Orna Therapeutics
Company Type: Therapeutic development
Main focus: Developing their circular RNA technology platform, oRNA®, and lipid nanoparticle (LNP) delivery methods
Company stage: Clinical
Diseases: B-cell-driven autoimmune diseases, B-cell malignancies, Sickle cell disease, β-thalassemia, and more
Genome-editing tool: Circular RNA
Funding stage: Series B
Location: Watertown, Massachusetts, USA
Website: https://www.ornatx.com/
Pipeline: https://www.ornatx.com/our-pipeline/
Partners:
Orna Therapeutics is a biotechnology company that specialises in the development of novel RNA-based therapeutics. Their primary focus lies in developing and advancing circular RNA (oRNA®) technology and lipid nanoparticle (LNP) delivery systems to enhance the stability, efficiency, and delivery of RNA-based medicines. Their goal is to address several diseases such as various cancers and autoimmune diseases through the use of circular RNA. In May 2024, Orna Therapeutics acquired ReNAgade Therapeutics, which brought ReNAgade’s broad portfolio of LNP-based RNA delivery systems and comprehensive editing programs to Orna. Read more about the takeover in the official press release here.
